BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/22/2021 8:09:41 AM | Browse: 771 | Download: 1384
 |
Received |
|
2021-05-08 12:46 |
|
Peer-Review Started |
|
2021-05-08 12:48 |
|
First Decision by Editorial Office Director |
|
2021-05-13 21:54 |
|
Return for Revision |
|
2021-05-13 21:54 |
|
Revised |
|
2021-05-18 14:19 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-08-18 03:20 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-08-18 09:25 |
|
Articles in Press |
|
2021-08-18 09:25 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-09-17 03:00 |
|
Publish the Manuscript Online |
|
2021-09-22 08:09 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Drug-induced liver injury and COVID-19: A review for clinical practice
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Gabriela Xavier Ortiz, Gabriele Lenhart, Matheus William Becker, Karin Hepp Schwambach, Cristiane Valle Tovo and Carine Raquel Blatt |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Matheus William Becker, MSc, Pharmacist, Research Scientist, Graduate Program in Medicine Hepatology, Federal University of Health Sciences of Porto Alegre, Sarmento Leite, 245 Street, Porto Alegre 90050-170, Rio Grande do Sul, Brazil. matheuswbecker@gmail.com |
| Key Words |
Liver injury; Chemical and drug-induced liver injury; COVID-19; SARS-CoV-2; Pharmacovigilance |
| Core Tip |
Coronavirus disease 2019 (COVID-19) is a multisystemic disease, and liver manifestations are an important aspect to be considered. One should pay attention to drug-induced liver injury, especially considering the off-label use of drugs in prophylactic and therapeutic regimens applied on large scales. A review of liver damage in patients with COVID-19 returned three studies involving remdesivir, tocilizumab, and a pharmacovigilance study. Liver disorders in COVID-19 patients and the use of several concomitant off-label drugs — potentially causing further liver damage — should be a warning sign for rapid identification and early intervention, thus preventing severe impairment in patients. |
| Publish Date |
2021-09-22 08:09 |
| Citation |
Ortiz GX, Lenhart G, Becker MW, Schwambach KH, Tovo CV, Blatt CR. Drug-induced liver injury and COVID-19: A review for clinical practice. World J Hepatol 2021; 13(9): 1143-1153 |
| URL |
https://www.wjgnet.com/1948-5182/full/v13/i9/1143.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v13.i9.1143 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
